



Press Release Contact Information:

Shushmul Maheshwari
RNCOS
CEO
29, 1st Floor, Patparganj Industrial area
Delhi, New Delhi
India, 110092
Voice: 91-11-4214-1229
Fax: 91-11-4214-1229
E-Mail: [Email us Here](mailto:info@rncos.com)
Website: [Visit Our Website](http://www.rncos.com)

Fast Developing mAb Market Poised to Hit 13.35% Growth

The future of monoclonal antibodies (mAb) seems healthy as the market is expected to grow at a CAGR of 13.35% till 2011, says RNCOS.

/24-7PressRelease/ - New Delhi, India, July 18, 2008 - A new research report, "Global Protein Therapeutics Market Analysis", by RNCOS reveals that the monoclonal antibodies (mAb) market is expected to grow at a CAGR of 13.35% through 2011.

As per the report, mAbs have shorter clinical trial period and faster development timeline in comparison to other drugs that ensures high success rate in development and launching of a mAb on the market. In 2006, about 17 therapeutic mAbs were available in the US market with over 40 new mAb-based therapies in Phase II or Phase III, or earlier stages of clinical development. On the basis of past approval rates, it is expected that 11 mAb products, currently in the pipeline, will be approved by the US Food and Drug Administration. Thus, the number of mAbs will be double the number of present mAbs and this will also lead to a radical rise in revenue generation.

The report identifies the rising number of AIDS and cancer patients as a major future driver for mAb market. The gradually ageing populations in developed as well as developing countries are leading to a rise in the number of new cancer cases, which are expected to rise from 10 Million in 2000 to 15 Million in 2020. Also, the ability to prevent spreading of disease-inducing target cells without damaging healthy cells in the adjacent tissues distinguishes mAbs from other therapies and acts as a key driver for the market. mAb drugs attack specific antigens within cells, tissues and organs without any off-target effects, and thereby have minimum side effects. Thus, due to this feature, mAbs are commercially feasible and successfully used in clinical applications.

The RNCOS research report forecasts that AIIDS (Immune and inflammatory Disorders) and Oncology treatments, at 37% and 47% respectively, will account for the maximum share in the mAb market by 2011.

"Global Protein Therapeutics Market Analysis" provides extensive research and objective analysis on the global protein therapeutics industry. It provides detailed overview of various protein therapeutics used for disease prevention, drivers, market size, key geographical markets, major areas of application, opportunities and challenges critical for the success of the industry.

For more information visit: <http://rncos.com/Report/IM557.htm>

Current Industry News: <http://www.rncos.com/Blog/>

About RNCOS

RNCOS, incorporated in 2002, provides Market Research Reports for your business needs and aims to put an end to your information pursuit. Our expertise in gathering global business information for industry research, corporate training, growth consulting, and business consulting, brings reputed companies and firms to us for business enhancement solutions. We can be your one-stop-shop for Industry research information and niche market analysis.